F. EXPERIMENTAL ENDPOINT CRITERIA 1. At what planned study time point(s) and/or clinical sign(s) will animals be euthanized? 2. Prior to these planned study endpoints, what criteria and/or specific clinical signs will be used for euthanasia? G. SPECIAL CONSIDERATIONS 1. natural pathogens Use of human samples requires IBC approval – Will materials potentially transmitting infections agents (i.e., human or murine derived tumor cell lines or other) be administered to the animals? Yes No If yes, describe, indicating whether tests (blood, serum, etc.) or other determinations have been conducted to assure the lines/materials are non-infectious regarding natural pathogens: 2. hazardous materials Use of all of the following requires IBC approval – Does this work involve any of the following materials: a. Radioactive No Yes If yes, list the material(s): b. Infectious Agents No Yes If yes, list the material(s): c. Recombinant DNA No Yes If yes, list the material(s): d. Toxic/Hazardous/Carcinogenic No Yes If yes, list the material(s): IBC APPROVAL If YES to G1 (if using human samples) or G2 above, provide the IBC protocol number and attach the IBC approval document to this protocol. This IACUC protocol cannot be approved until all relevant IBC approvals have been obtained. If you have an approved IBC protocol for the use of the above agent(s), you may be able to amend the existing IBC protocol to associate it with this IACUC protocol. Contact to determine if an amendment is appropriate. If you do not have an IBC protocol for the use of the above agent(s), please contact to coordinate submission of an IBC protocol. 3. explosive agent(s) Use of these agents is highly discouraged and may be denied; is ether or another explosive agent to be used? No Yes If yes, list the agent(s) and describe how security is maintained:
F. EXPERIMENTAL ENDPOINT CRITERIA 1. At what planned study time point(s) and/or clinical sign(s) will animals be euthanized? 2. Prior to these planned study endpoints, what criteria and/or specific clinical signs will be used for euthanasia? G. SPECIAL CONSIDERATIONS 1. natural pathogens – Use of human samples requires IBC approval Will materials potentially transmitting infections agents (i.e., human or murine derived tumor cell lines or other) be administered to the animals? Yes No If yes, describe, indicating whether tests (blood, serum, etc.) or other determinations have been conducted to assure the lines/materials are non-infectious regarding natural pathogens: 2. hazardous materials – Use of all of the following requires IBC approval Does this work involve any of the following materials: a. Radioactive No Yes If yes, list the material(s): b. Infectious Agents No Yes If yes, list the material(s): c. Recombinant DNA No Yes If yes, list the material(s): d. Toxic/Hazardous/Carcinogenic No Yes If yes, list the material(s): IBC APPROVAL If YES to G1 (if using human samples) or G2 above, provide the IBC protocol number and attach the IBC approval document to this protocol. This IACUC protocol cannot be approved until all relevant IBC approvals have been obtained. If you have an approved IBC protocol for the use of the above agent(s), you may be able to amend the existing IBC protocol to associate it with this IACUC protocol. Contact to determine if an amendment is appropriate. If you do not have an IBC protocol for the use of the above agent(s), please contact to coordinate submission of an IBC protocol. 3. explosive agent(s) Use of these agents is highly discouraged and may be denied; is ether or another explosive agent to be used? No Yes If yes, list the agent(s) and describe how security is maintained:
SUNY%20Downstate%20Animal%20Use%20Protocol%20Form.docx